266 related articles for article (PubMed ID: 28389531)
1. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
Manic G; Signore M; Sistigu A; Russo G; Corradi F; Siteni S; Musella M; Vitale S; De Angelis ML; Pallocca M; Amoreo CA; Sperati F; Di Franco S; Barresi S; Policicchio E; De Luca G; De Nicola F; Mottolese M; Zeuner A; Fanciulli M; Stassi G; Maugeri-Saccà M; Baiocchi M; Tartaglia M; Vitale I; De Maria R
Gut; 2018 May; 67(5):903-917. PubMed ID: 28389531
[TBL] [Abstract][Full Text] [Related]
2. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
[TBL] [Abstract][Full Text] [Related]
3. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
4. Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Manic G; Musella M; Corradi F; Sistigu A; Vitale S; Soliman Abdel Rehim S; Mattiello L; Malacaria E; Galassi C; Signore M; Pallocca M; Scalera S; Goeman F; De Nicola F; Guarracino A; Pennisi R; Antonangeli F; Sperati F; Baiocchi M; Biffoni M; Fanciulli M; Maugeri-Saccà M; Franchitto A; Pichierri P; De Maria R; Vitale I
Cell Death Differ; 2021 Jul; 28(7):2060-2082. PubMed ID: 33531658
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
Lombardo Y; Scopelliti A; Cammareri P; Todaro M; Iovino F; Ricci-Vitiani L; Gulotta G; Dieli F; de Maria R; Stassi G
Gastroenterology; 2011 Jan; 140(1):297-309. PubMed ID: 20951698
[TBL] [Abstract][Full Text] [Related]
7. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
8. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
[TBL] [Abstract][Full Text] [Related]
9. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling.
Goldstein M; Roos WP; Kaina B
Toxicol Appl Pharmacol; 2008 May; 229(1):20-32. PubMed ID: 18289623
[TBL] [Abstract][Full Text] [Related]
11. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
12. Replication stress response in cancer stem cells as a target for chemotherapy.
Manic G; Sistigu A; Corradi F; Musella M; De Maria R; Vitale I
Semin Cancer Biol; 2018 Dec; 53():31-41. PubMed ID: 30081229
[TBL] [Abstract][Full Text] [Related]
13. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Durinikova E; Reilly NM; Buzo K; Mariella E; Chilà R; Lorenzato A; Dias JML; Grasso G; Pisati F; Lamba S; Corti G; Degasperi A; Cancelliere C; Mauri G; Andrei P; Linnebacher M; Marsoni S; Siena S; Sartore-Bianchi A; Nik-Zainal S; Di Nicolantonio F; Bardelli A; Arena S
Clin Cancer Res; 2022 Sep; 28(17):3874-3889. PubMed ID: 35881546
[TBL] [Abstract][Full Text] [Related]
14. Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive.
Guo N; Faller DV; Vaziri C
Cell Growth Differ; 2002 Feb; 13(2):77-86. PubMed ID: 11864911
[TBL] [Abstract][Full Text] [Related]
15. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
17. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
19. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53.
Segeren HA; van Liere EA; Riemers FM; de Bruin A; Westendorp B
Oncogene; 2022 May; 41(19):2719-2733. PubMed ID: 35393546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
